GE
-
Global generic drug markets will grow to US$221 billion by 2016
Driven by the need to control costs, the use of generic drugs has grown considerably in recent years, even in markets where traditionally they have not been favored.
GE | 23 May 2012
-
US Supreme Court clears way for generic patent challenges
After the ruling, generic manufacturers will now be able to challenge the content of patent descriptions and, if successful, ultimately force approval of the ANDA. Writing for the Court in a unanimous decision, Justice Elena Kagan chastised the FDA for using ambiguous or opaque guidelines and forms that lend to the confusion surrounding patent decisions.
GE | 18 May 2012
-
Kuehne + Nagel launches innovative airfreight solution for pharmaceutical products
KN PharmaChain offers – among other features – door-to-door temperature control, a 24 hour alert system, optional wireless temperature measuring and best practice (GxP) standards for facilities, working processes and training programmes.
GE | 08 May 2012
-
Phosphagenics signs agreement with Nippon Zoki
The companies have struck a material transfer agreement which enables Nippon Zoki to test and assess Phosphagenics’ patented TPM/diclofenac topical non-steroidal pain formulation for its suitability as a prescription item in the USA and Japanese markets.
GE | 03 May 2012
-
GE Healthcare opens training center in China
GE Healthcare announced the official opening of its expanded Fast Trak Training Center in Shanghai, China.
GE | 20 April 2012
-
Gerresheimer acquires Neutral Glass
Gerresheimer AG is committed to growth in the emerging markets. It acquires a majority shareholding in the Indian company Neutral Glass & Allied Industries to help it achieve this aim.
GE | 19 April 2012
-
Refinements in inhaled drug delivery enhances growth prospects as global markets emerge
Survey finds evolving device technologies creating opportunities for drug developers, according to Greystone Research Associates.
GE | 10 April 2012
-
Salix initiates Target 3 phase 3 study
Salix initiates Target 3 phase 3 study to assess repeat treatment efficacy and safety of Rifaximin 550MG TID in subjects with irritable bowel syndrome with diarrhea
GE | 06 April 2012
-
apceth, Indivumed to develop biomarker platform for targeted cellular therapies
apceth and Indivumed have entered into a partnership for the development of a predominantly tissue-based biomarker strategy for the treatment of solid cancers with cellular and / or gene therapeutics.
GE | 27 March 2012
-
GEA Pharma Systems develops inline moisture sensor
GEA Pharma Systems, in co-operation with NDC, has developed an inline moisture sensor for pharmaceutical drying systems.
GE | 26 March 2012
